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Introduction
Proximal oesophageal cancer occurs relatively 
rarely, constituting approximately 10% of oesoph-
ageal cancers. In the case of cancer located in the 
cervical oesophagus, the recommended treatment 
is radical chemo-radiation therapy, whereas surgical 
treatment, i.e., free intestinal flap, free myocutane-
ous flap or gastric conduit, is rarely indicated [1–3]. 
In the case of relapse, or in patients who are not can-
didates for curative-intent therapy, palliative treat-
ment is usually indicated. The aims of the palliative 
therapy are: restoration of patency of the oesopha-
gus to enable, at least partial, oral feeding, and im-
provement of nutritional status.
The most often used methods of palliative treat-
ment include oesophageal stenting, gastrostomy or 
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A b s t r a c t
Introduction: Proximally located oesophageal cancer poses an especially difficult problem in terms of restoration of 
patency and the stenting procedure. Supplementary percutaneous endoscopic gastrostomy (PEG) may be useful in 
these patients. 
Aim: To assess the safety of the stenting procedure in the proximal oesophagus in patients with unresectable upper 
oesophageal cancer, performed simultaneously with PEG insertion.
Material and methods: Patients with obstructing upper oesophageal tumours were scheduled for an oesophageal 
stenting procedure and simultaneous PEG insertion. Degree of dysphagia, body weight loss, daily energy require-
ment, body mass index and performance status before and after the stenting procedure as well as complications 
were assessed. 
Results: Forty-five patients aged 19–88 years were included in the study. Six of them had a fistula to the trachea and 
underwent stenting of the oesophagus or both the oesophagus and the airway. The technical success rate was 100%. 
Following the procedure all patients were able to swallow fluids and semi-liquids, and PEG was used as the primary 
feeding route. Body mass index increased from 20.4 to 21.1 (p = 0.0001), body weight gain improved from –10.1 to 
+2.0 kg and metabolic requirements improved (p = 0.0001). Also, the Karnofsky score improved significantly (56.7 vs. 
65.1, p = 0.0001). Mean survival time was 133 days (range: 36–378). 
Conclusions: Stenting of the proximal oesophagus with simultaneous PEG is a safe procedure, allowing the patients 
to resume oral intake of liquids whilst improving nutritional status and general performance, with an acceptable rate 
of complications.
Key words: oesophageal cancer, stenting, percutaneous endoscopic gastrostomy, fistula.
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feeding jejunostomy, chemo- and/or radiation ther-
apy, and laser or photodynamic intraluminal therapy. 
The use of covered self-expandable metallic stents 
(SEMS) in the upper oesophagus is controversial, 
due to the relatively frequent intolerable discomfort 
in the neck, globus sensation, impairment of the 
swallowing act, chest pain, and complications such 
as perforation or migration. New, low-profile stents 
are reportedly better tolerated [4, 5].
Due to the development of endoscopic surgery, 
technological progress in the available oesophageal 
and airway stents as well as percutaneous endoscop-
ic gastrostomy (PEG) technique, together with the 
growing experience of medical centres performing 
such procedures, it is possible to expand the range 
of palliative treatment in this group of patients.
Aim
In the present study, we assessed the safety and 
effectiveness of the stenting procedure in the proxi-
mal oesophagus in patients with unresectable upper 
oesophageal cancer, performed simultaneously with 
PEG insertion. The aims of the palliative therapy are 
restoration of patency of the oesophagus to enable, 
at least partial, oral feeding, and improvement of nu-
tritional status and quality of life.
Material and methods
The study included data for a consecutive group 
of patients treated for unresectable upper oesoph-
ageal cancer with or without oesophago-airway 
fistula (OAF) between 2003 and 2016. Institutional 
review board approval was waived due to the retro-
spective character of the study. For the same reason, 
patients’ informed consent was not obtained.
The pre-procedure work-up in all patients included: 
–  endoscopic examination – oesophagoscopy with 
the assessment of oesophageal patency and the 
length of the involved segment, and bronchoscopy;
–  assessment of the degree of dysphagia;
–  assessment of body mass index (BMI), body weight 
loss, and basal metabolic rate (BMR) requirement 
calculated using the Harris-Benedict equation: 
for men BMR = 88.362 + (13.397 × weight [kg]) + 
(4.799 × height [cm]) – (5.677 × age [years]), and 
for women BMR = 447.593 + (9.247 × weight [kg]) 
+ (3.098 × height [cm]) – (4.330 × age [years]) [6], 
–  in patients with OAF the degree of dyspnoea was 
additionally assessed (Table I).
Mean degree of dysphagia before and after 
the stenting procedure was assessed according to 
a four-grade scale [7]: 0 – no dysphagia; 1 – able to 
swallow semi-liquid food; 2 – able to swallow liq-
uids; 3 – unable to swallow liquids and saliva.
Degree of stenosis of bronchial lumen and the 
degree of dyspnoea were assessed according to 
the original, four-grade scale [8]: 0 – stenosis of the 
bronchial lumen < 30%, no dyspnoea; 1 – stenosis 
of the bronchial lumen 30–50%, dyspnoea on exer-
cise; 2 – stenosis of the bronchial lumen 50–70%, 
dyspnoea on short-distance walk; 3 – stenosis of the 
bronchial lumen > 70%, dyspnoea on rest.
Patients with oesophageal fistula were classified 
according to the original classification depending on 
the fistula location [8]: type I – oesophageal-medi-
astinal fistula, without penetration to the bronchial 
tree; type II – oesophageal fistula penetrating to the 
trachea; type III – oesophageal fistula penetrating to 
the carina and/or main bronchus/bronchi.
Patients’ performance status before and after 
stenting was assessed based on the Karnofsky score  
[9]. Patients whose performance was assessed be-
low 40 on the Karnofsky scale were excluded from 
the study group.
Qualification criteria for oesophageal stenting 
and airway stenting were as follows: 
1. For oesophageal stenting:
– upper oesophageal tumour;
– endoscopically confirmed OAF.
2. For double stenting:
– airway stenosis of 2nd–3rd degree or fistula not 
covered by the oesophageal SEMS. 
Intervention
Oesophageal stenting was conducted under 
general anaesthesia. The location of stenosis and 
the distance from the upper oesophageal sphincter 
were endoscopically identified and then the dila-
tation was performed with Savary-Gilliard dilators, 
up to the size of 10–14 Fr. After the dilatation, the 
length of the involved segment was assessed using 
a small-diameter endoscope. Partially covered SEMS 
7–12 cm long and with diameter of 18 mm (Ultraflex 
Boston Scientific, Natick, USA) were used. A guide-
wire was inserted and the oesophageal stent was 
introduced over it. Generally, if the tumour was lo-
cated below the upper oesophageal sphincter, the 
SEMS was positioned with its proximal end at least 
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2 cm below the sphincter. However, in patients in 
whom the tumour involved the sphincter, the stent 
was deployed with its proximal end slightly below 
the proximal margin of the tumour. In patients with 
OAF, the SEMS was positioned to cover 2–4 cm of 
the oesophageal wall above and below the fistula. 
Next, the stent location was checked endoscopically. 
If necessary, stent reposition was performed or an 
additional stent was inserted. 
A  percutaneous endoscopic gastrostomy tube 
was inserted using the standard ‘pull technique’ [10]. 
Airway stenting, if indicated, was performed 
during the same general anaesthesia. Routinely, air-
way stenting was performed first to avoid its poten-
tially fatal compression by the expanding oesopha-
geal stent. Prior to implantation of the stent, airway 
patency was restored mechanically using rigid bron-
choscopes (Karl Storz GmbH, Tuttlingen, Germany) 
no. 6.5, 7.5 and 8.5, or using argon plasma coagu-
lation (APC Covidien, Minneapolis, USA) and laser 
(MY 40 1.3, KLS Martin GmbH & Co. KG, Freiburg, 
Germany) [11]. Partially covered SEMS (Ultraflex, 
Boston Scientific, Natick, MA, USA) were implanted 
under endoscopic control [12].
Follow-up
Patients received follow-up examinations 1 day 
after surgery, and every 30 days thereafter. When 
necessary, the follow-up examinations were con-
ducted by telephone. Patients underwent the fol-
lowing assessments: chest X-ray, esophagoscopy, 
bronchoscopy, and computed tomography (CT). The 
follow-up examinations determined the patient’s 
general condition, quality of life, dyspnoea (assessed 
on a breath scale), and difficulties in swallowing.
Table I. Clinical and demographic data of the patients
Measurement All patients Patients without 
fistula
Patients with 
fistula
Number of patients 45 39 6
Age, mean (range) 60.3 (19–88) 63.8 (21–88) 58.7 (19–82)
Males/females 38/7 34/5 4/2
Type of cancer:
SCC 44 39 5
SCEC 1 1
Mean length (range) of the involved oesophageal segment [cm] 5.8 (3–7) 5.57 (4–7) 5.9 (3–7)
Location of tracheal stricture in the airway > 30% 4 1 3
Location of tracheal stricture in the airway < 30% 21 20 1
Type of fistula:
I 2 2
II 4 4
Cause of death: 45 39 6
Cachexia 36 36
Dyspnoea 6 3 3
Other 3 6 3
Mean survival time (range) [days] 133 (range: 36–378) 73.4 (range: 43–154)
Adjuvant therapy: 32 28 4
Cht 14 16 1
Cht + Rth 18 12 3
Cht – chemotherapy, Cht + Rth – chemo-radiotherapy, SCC – squamous cell carcinoma, SCEC – small-cell oesophageal cancer.
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Statistical analysis
All statistical analyses were performed with the 
Statistica 10 PL software package (StatSoft, USA). The 
following tests were used: Gehan-Wilcoxon, and Kru-
skal-Wallis c2 test. The dependent variable regression 
test was used to analyse data collected before and af-
ter surgery. The analyses included survival, dysphagia, 
assessment of BMI, body weight loss, and basal meta-
bolic rate requirement, quality of life (according to the 
Karnofsky scale), the influence of adjuvant therapy 
(chemotherapy and/or radiotherapy). P-values < 0.05 
were considered statistically significant.  
Results
Patient characteristics
There were 45 patients, 38 (84.4%) males, mean 
age 60.3 years (range: 19–88), who underwent a si-
multaneous stenting procedure and PEG. Forty-four 
(97.8%) (84.4%) patients had squamous-cell oe-
sophageal cancer, and 1 (2.2%) had small-cell oe-
sophageal cancer. 
In 35 (77.7%) patients the proximal margin of the 
tumour was located 18–21 cm from the incisors and 
in 10 (22.3%) patients it was located 22–24 cm from 
the incisors. In 6 (13.3%) patients OAF was present: 
in 2 (4.4%) patients type I, in 4 (8.8%) patients type II. 
In 1 (2.2%) patient double stenting was performed 
due to the tumour compressing the trachea. In 
2 (4.4%) patients complete sealing of the OAF by the 
oesophageal SEMS was achieved, and in 3 (6.6%) 
patients with OAF, double stenting of the oesopha-
gus and trachea using SEMS was conducted. 
Two (4.4%) patients had a  history of surgical 
procedures (cholecystectomy) within the upper ab-
domen. In 33 (73.3.8%) patients the PEG catheter 
was inserted through the stent, and in 12 (26.7%) 
patients before stent implantation (p = 0.021).
Quality of life
The restoration of oesophageal patency was 
achieved in all the patients after the stenting proce-
dure. The degree of dysphagia improved significantly 
(2.9 vs. 1.0, p = 0.0001) (Figure 1). The mean body 
weight loss within the last 6 months before the proce-
dure was –10.1 kg and after the stenting it improved 
to +2.0 kg (p = 0.0001) (Figure 2). This corresponded 
with a significant increase of mean BMI (20.4 vs. 21.1, 
p = 0.0001) (Figure 3). Mean loss in daily basal meta-
bolic rate requirement before the stenting procedure 
was 8.9%. After the stenting procedure all patients 
were able to fully cover their daily basal metabol-
ic requirement. Three of them (6.6%) reported body 
weight loss (2, 3, 7 kg), in 14 (31.1%) patients body 
weight remained stable, and in 28 (62.2%) patients 
body weight gain was observed from 2 to 9 kg, which 
was statistically significant (p = 0.0001) (Figure 4).
Statistically significant improvement in the per-
formance status was also observed. The mean Karn-
ofsky score improved from 56.7 to 65.1 (p = 0.0001) 
(Figure 5).
After the stenting 33 (73.3%) patients were 
able to swallow semi-liquid and liquid food and 11 
(24.4%) liquid food.
Thirty-two (71.1%) patients received adjuvant 
chemo- and/or radiation therapy (Table I). These 
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Figure 1. Dysphagia before and after stenting
 Before After
 stenting stenting
Figure 2. Weight loss before and after stenting
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treatments had no effects on re-interventions or pa-
tient survival (p = 0.36).
Mean survival time was 133 days (range: 36–378) 
and for patients with OAF 73.4 days (range: 43–154).
Complications
Most complications of oesophageal stenting and 
PEG insertion were mild. Twenty-five (55.5%) pa-
tients had discomfort in the neck, 17 (37.7%) had 
the feeling of a foreign body in the oesophagus, in 
2 (4.4%) patients repeat restoration of patency was 
necessary due to the overgrowth of granulation tis-
sue, in 1 (2.2%) patient a re-stenting procedure was 
performed by placing another stent into the first 
one, and in 1 (2.2%) case the stent was removed and 
the stenting procedure was repeated.
Buried bumper syndrome occurred in 2 (2.4%) 
patients following PEG insertion; in 1 (2.2%) of 
them endoscopic reposition was performed and 
the patients were able to resume feeding via PEG 
within 10 days, whereas in 1 (2.2%) patient the 
PEG was removed and re-inserted 21 days later. 
In 3 (6.6%) patients soft tissue infection occurred 
due to a  leak around the PEG tube, in 1 (2.2%) 
patient the PEG was removed, and in 2 (4.4%) 
patients infection subsided following temporary 
discontinuation of feeding via PEG and antibiotic 
therapy. 
Severe postoperative complications occurred in 
1 (2.2%) patient due to colonic perforation during 
PEG insertion. The patient had undergone left-sid-
ed hemicolectomy in the past. Laparotomy was per-
formed, the perforation was sutured and the gas-
trostomy tube was inserted. The patient resumed 
oral nutrition and was discharged home. 
Discussion
Patients with malignant obstruction of the upper 
oesophagus are characterized by higher incidence 
of vocal cords paralysis, risk of OAF formation, rapid 
body weight loss, and choking with saliva and food 
that lead to recurrent refractory pneumonia. These 
factors are associated with poor quality of life and 
progressive disability. 
Traditional palliative treatment has been limit-
ed to gastrostomy or jejunostomy and adjuvant ra-
dio-chemotherapy in fit patients. These measures, 
however, do not solve the problems of dysphagia 
and aspiration of food and saliva to the airway. Also, 
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Figure 3. Gain of BMI in patients before and af-
ter stenting 
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Figure 4. Energy requirement before and after 
stenting
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psychological aspects should be noted, i.e. increas-
ing anxiety and depression. 
Restoration of the patency and stenting in the 
upper one-third of the oesophagus is technically 
more challenging than in its thoracic part, due to 
the anatomical relationships. These difficulties are 
associated with limited ability of insufflation, high 
resting pressure within the lower pharynx and upper 
oesophageal sphincter as well as close vicinity of the 
lower larynx and trachea. The rate of improper stent 
implantation in the upper oesophagus is reported to 
be 7–23% [13].  
An additional problem is the short margin (or 
no margin at all) between the upper oesophageal 
sphincter and the tumour. Implantation of SEMS at 
the level of this sphincter usually leads to consider-
able discomfort and impairment of the swallowing 
act. Therefore, the result of restoration of patency 
and the stenting procedure is uncertain and does 
not guarantee full comfort of oral nutrition and 
a sufficient supply of nutrients [14]. 
Management of unresectable oesophageal can-
cer usually requires oesophageal stenting, but can 
also require simultaneous stenting of the airway if 
tracheal stenosis or OAF is present. Verschuur et al. 
used covered SEMS and reported 1 case of tracheal 
compression that required tracheal stenting, among 
104 treated patients. In our study, tracheal compres-
sion that required stenting occurred in 1 of 45 pa-
tients [3, 15, 16].
Formation of an OAF is a bad prognostic factor 
for survival. It is estimated that oesophageal fistu-
las occur in 0.9–18% of patients with oesophageal 
cancer as a  result of direct neoplastic infiltration 
and necrosis between the oesophagus and bronchi-
al tree or mediastinum. According to most authors, 
covered SEMS are recommended for oesophageal 
stenting and covered SEMS or silicone Y-stents are 
recommended for stenting of the bronchial tree 
[17–20]. 
Despite the restrictions described above, effec-
tiveness of stenting procedures in malignant proxi-
mal oesophageal stenoses is in the range 87–100% 
in experienced centres. In our group, satisfactory oe-
sophageal patency was obtained in all the patients 
and dysphagia subsided, enabling oral nutrition; in 
the literature this rate ranges between 73% and 
100% [21, 22].
Despite restoration of oesophageal patency, full 
coverage of nutritional requirements is not always 
possible. During the early post-stenting period pa-
tients report discomfort in the neck, particularly on 
swallowing, and the feeling of a foreign body in the 
oesophagus. These symptoms, impairing patients’ 
quality of life, can be temporary, but remain in up 
to 30% of patients [23–26]. This problem can be, at 
least partially, overcome by creation of a supplemen-
tary route of enteral feeding.
Reportedly, the most frequent complication is 
late obstruction of the stent, caused by the over-
growth of granulation tissue, which can occur in up 
to 28% of patients in the case of partially covered 
stents and in 13% in the case of plastic stents [27, 
28]. In our study the rate of late obstructions was 
8.8%. In these patients stent removal or an addition-
al telescopic stent-in-stent implantation is usually 
required, a procedure that is technically challenging. 
Another complication, which can occur early or late, 
is migration of the stent, which happens in 6–12% 
of patients. The stent can migrate towards the hy-
popharynx, leading to life-threatening dyspnoea, 
or distally [29]. In our group, similar as reported by 
Eleftheriadis et al. and Fujita et al., migration was 
not observed [20, 23].
Generally, oesophageal stenting is a  relatively 
safe procedure; however, according to some reports, 
the rate of complications can reach 34% with mor-
tality of 0–5%. [27]. 
According to the available literature, for stenting 
of the upper oesophagus most authors use covered 
stents or self-expandable plastic stents (SEPS). In 
our institution, partially covered SEMS are used be-
cause their non-covered ends provide some protec-
tion from migration, even during pulling the bumper 
of the PEG catheter through the stent. Indeed, there 
was no stent migration in our group. An additional 
advantage is the technically simple, precise implan-
tation under endoscopic control. If necessary, par-
tially covered SEMS can be removed. 
According to Mariette et al., patients who re-
ceive < 75% of energy requirement are at risk of 
malnutrition, whereas patients whose supply is 
< 50% of their energy requirement should receive 
enteral nutrition [30]. Reportedly, 60–80% of pa-
tients with oesophageal cancer are malnourished 
[31–33]. Although restoration of oesophageal pa-
tency enables oral nutrition, it is often not suffi-
cient in severely malnourished patients. The PEG 
insertion as an alternative method of nutrition is 
an effective way to provide adequate protein and 
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caloric supply. In our group, improvement of pa-
tients’ metabolic condition was observed after PEG 
implantation (significant increase in BMI and body 
weight) with an acceptable rate of perioperative 
complications. Other authors also observed an im-
provement of patients’ metabolic condition after 
routine nutrition via gastrostomy, often indicated 
in surgically treated patients with head and neck 
cancers [34]. In a  prospective study Löser et al. 
observed that before the introduction of nutrition-
al treatment via PEG, mean body weight loss was 
11.35 kg, and after that it was reduced to 3.75 kg. 
This kind of nutrition also leads to an increase in 
caloric intake of approximately 30% compared to 
those receiving only oral nutrition, but can have no 
influence on the increase in fat free mass, skeletal 
mass or BMI [35–37]. 
In our study the PEG was inserted using the 
‘pull’ technique described by Gauderer et al. [10]. 
Meticulous technique of PEG insertion is crucial 
for avoiding complications. Previous surgery in the 
upper abdomen is considered a  relative contrain-
dication, which is supported by our results. Among 
our patients, 4 patients had previous upper abdom-
inal surgery, and one of the injuries to the colon 
occurred in this group. Some authors consider that 
the inadequate experience of the endoscopist per-
forming the procedure is one of the risk factors [31, 
38]. 
It is possible to insert the PEG after or before oe-
sophageal stenting. It should be noted that the PEG 
catheter can be pulled through the stent only if the 
stent is fully expanded, which is not always possi-
ble to achieve. Also, if a  low-profile SEMS (12 mm 
in diameter) is used, insertion of the PEG will not 
be possible thereafter. In the case of patients with 
stenosis located below the upper sphincter, pulling 
through the catheter is easier, because stent expan-
sion is usually complete. Stent migration after pull-
ing the PEG catheter was not observed in our group. 
Insertion of the PEG catheter through the stent is 
also suggested by some reports concerning the im-
plantation of cancer cells along the PEG channel in 
the gastric wall and the abdominal wall. The risk 
of such implants is estimated to be approximately 
1% [39, 40]. Moreover, the clinical relevance of such 
implants is uncertain because of the short life ex-
pectancy in this group of patients. The presence of 
cancer implants around the PEG was not observed 
in our group. 
Conclusions
Stenting of the proximal oesophagus with simul-
taneous PEG is a relatively safe procedure. It allows 
the patients to resume oral intake of liquids. Sup-
plementary feeding via the PEG tube allows for ade-
quate coverage of nutritional requirements, improv-
ing nutritional status and general performance, with 
an acceptable rate of complications. 
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